WSJ
Overall, looks rather positive. Time to sell?
Also, John Mauldin is talking about the biotech stocks and how they may become the next "it".
I like the idea of biotech because of its inherent exposure to the so-called positive "Black Swans".
In some ways, they are similar to book publishers: if one book out of 10/20/30 becomes a hit, the business is good. Downside is somewhat limited and the potential upside can be very significant. And the product is super scalable, too. Unlike dentistry (I am borrowing heavily from Taleb here).